While the most common HNF1A-MODY CVD risk is similar to that of T2DM, which is usually treated with sulfonylureas, the GLP-1 RA used to treat T2DM has recently been shown to be effective in treating HNF1A-MODY as well (75, 76). The gene discussed is HNF1A; the disease is type 2 diabetes mellitus.